By Scott Wooldridge The climate for investment in medical device companies is improving but getting tighter, as biotech and pharma horn in on the recovering economy, according to a pair of medtech CEOs speaking at last night’s DeviceTalks: Minnesota event. Entellus Medical (NSDQ:ENTL) CEO Bob White and Martha Shadan, president & CEO at Rotation Medical, spoke with LifeScience Alley CEO Shaye […]
Entellus said earlier this month that it signed a distribution agreement with Fiagon NA Corp. to purchase and resell Fiagon’s surgical navigation systems, components and parts in the U.S. and its territories. The agreement will make Entellus the exclusive distributor of certain Fiagon systems and parts to ear, nose and throat physicians offices, clinics and surgery […]
NuVasive Inc. (NSDQ:NUVA) announced a flurry of new executive assignments yesterday as it reorganizes its leadership team under new CEO Gregory Lucier, who took over the position in May from ousted Alex Lukianov. NuVasive 14-year vet Pat Miles will stay on as COO and president, a position he was appointed to earlier this year, NuVasive said. […]
With 2014 a rebounding year for medical device and biopharmaceutical IPOs, 2015 should build further on that progress, a panel at the MedTech Investing Conference said this week.
Entellus Medical said yesterday that it plans to put nearly 4.4 million shares on the public markets by the end of the month as it readies its initial public offering.
Plymouth, Minn.-based Entellus said it plans to float 4.375 million shares at $15 to $17 each in the IPO, for a midpoint of $70 million.
Brian Farley knows a little something about building a successful medical device company from the ground up.
Back in 1995 Farley was the 1st employee of VNUS Medical Technologies, which developed a catheter-based treatment for venous insufficiency. During his tenure as VNUS CEO, the company went public in 2004 before being acquired by Covidien (NYSE:COV) for $440 million.
Tandem Diabetes Care Inc. raised $12 million of a $13.7 million funding round spread across eight investors.
Meanwhile, its flagship t:slim insulin pump is under 510(k) review with the FDA as an option for people with Type I diabetes, according to VentureWire.
The current offering, which opened last week, is a mixture of debt and options, according to regulatory filings. The investors were not named.
New data on patients implanted with a microchip designed to restore eyesight indicates that the device improved their vision enough to have an impact on their daily lives.
Retina Implant AG, the maker of a subrential implant designed to restore vision in people suffering from retinitus pigmentosa, said initial findings from the company’s second clinical trial showed that the first seven patients permanently implanted with the company’s device experienced restored useful visual function that enabled them to improve activities of daily living.
Medtronic Inc. (NYSE:MDT) said results from the Improve HF study demonstrate that select guideline-based outpatient heart failure measures can increase patient survival and might be useful for improving patient quality of care.
The Improve HF (The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting) study is the largest U.S.-based outpatient heart failure clinical study. The results of the study were published in the journal Circulation.